Dermatomyositis and polymyositis - treatment options
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 4
Abstract
Dermatomyositis (DM) and polymyositis (PM) are rare idiopathic inflammatory myopathies. The severity of DM and PM is highly variable ranging from mild muscle weakness in cases of benign course to oesophagus, respiratory muscle and cardiac involvement in cases of extremely severe course. Most patients are treated with glucocorticoids or combined therapy of glucocorticoids with methotrexate and/or azathioprine. The presence of antibodies, duration of the disease before treatment beginning, severity of respiratory muscle weakness, dysphagia, cardiac involvement and presence of malignant disease are some of the predictors of outcome and therapy response. The aim of this paper is to present current knowledge about DM and PM treatment possibilities, treatment recommendations and novel therapies as an alternative option for patients who fail to respond to standard pharmacotherapy.
Authors and Affiliations
Krzysztof Gutkowski, Andrzej Pluta
Keywords
Related Articles
- EP ID EP82406
- DOI -
- Views 89
- Downloads 0
Efficacy and safety of TNF inhibitors - results of randomized controlled clinical trials
TNF inhibitors were first approved for treatment of active rheumatoid arthritis (RA) in 1998. Since that time, a series of multicentre, randomized controlled trials have been evaluated in early and established RA, in p...
II Ogólnopolska Konferencja Zespół antyfosfolipidowy. Poznań, 17–18 marca 2006 r.
Diagnostic of neuropsychiatric complications in vascular diseases in the course of systemic connective tissue diseases
Neuropsychiatric complications of systemic connective tissue diseases are currently the subject of interest of neurologists and rheumatolgists. Since the time that the new neuroimaging technics and serological and cerebr...
Krzyżowo reagujące przeciwciała antyfosfolipidowe jako marker obecności endotoksyny w surowicach i płynach stawowych uzyskanych od pacjentów z zapaleniami stawów
Analizując grupy surowic i płynów stawowych pochodzące z różnych zapaleń stawów, autorzy zauważyli, że częstość występowania przeciwciał aCl w tych grupach była wysoka (ok. 30–40% – zbliżona do częstości w chorobach z au...
The Twentieth Congress of Russian Internists Centenary of the Russian Scientific Society of Internal Medicine Moscow, December 2-4, 2009